CDMO Capabilities
We provide drug substance development and manufacturing services across the entire lifecycle — helping you seamlessly transition from early development and clinical trials to commercial GMP supply.
Robust process development and manufacturing for complex, high value APIs across clinical and commercial stages — including GMP manufacturing for regulated markets.
Integrated peptide development and manufacturing solutions supporting early phase programs, clinical trials, and commercial supply using flexible technology platforms.
Tailored development of non infringing routes for complex molecules, with a focus on impurity control, reproducibility, and scalability for both clinical and commercial requirements.
From route scouting and feasibility to scale-up for clinical trials manufacturing, ensuring a smooth transition into validated GMP manufacturing.
Global standard GMP manufacturing (USFDA & EU GMP compliant) supporting Phase I–III clinical supply as well as long term commercial production.
What Sets Neuland Apart
A trusted partner for innovators seeking CDMO pharma manufacturing, clinical development support, and scalable commercial supply
Specialists in complex small molecules, Peptide APIs and niche therapeutic areas
Seamless support from early development and clinical trials to commercial GMP manufacturing
Strong track record of zero observation audits and global regulatory compliance
Continuous investment in technology, people and sustainable solutions
Evaluate Your Molecule With Us
Discuss your clinical trials manufacturing, scale up, or GMP manufacturing requirements with our scientific experts.
Whether you're looking to outsource drug manufacturing, optimize your process, or scale to commercial supply — we provide the expertise and infrastructure to support your program.
Confidential technical discussion • No obligation • NDA available on request
CDMO Insights: From Development to Commercial Success
CDMO API Manufacturing for Complex Molecules
Read the blog
How CDMO Partnerships Improve R&D ROI for Biopharma Companies
Read the blog
